These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30653217)

  • 1. Multiple Lesions in Irradiated Skin.
    Wetzel M; Jung JY; Brown TS
    JAMA Oncol; 2019 May; 5(5):728-729. PubMed ID: 30653217
    [No Abstract]   [Full Text] [Related]  

  • 2. Extensive thoracic skin lesion in a patient with history of breast cancer.
    López Rojo I; Rivas Fidalgo S; Gómez Valdazo A; Díaz Miguel M
    Cir Esp (Engl Ed); 2019; 97(6):346. PubMed ID: 30595224
    [No Abstract]   [Full Text] [Related]  

  • 3. Vismodegib in advanced basal-cell carcinoma.
    Babacan T; Sarici F; Altundag K
    N Engl J Med; 2012 Sep; 367(10):969-70; author reply 970. PubMed ID: 22931270
    [No Abstract]   [Full Text] [Related]  

  • 4. Indications and limitations of vismodegib for basal cell carcinoma.
    Yin VT; Sniegowski M; Esmaeli B
    JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179
    [No Abstract]   [Full Text] [Related]  

  • 5. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 6. Attacking the hedgehog pathway: video game or novel skin cancer therapy?
    DiBaise M
    JAAPA; 2014 Oct; 27(10):52-3. PubMed ID: 25251656
    [No Abstract]   [Full Text] [Related]  

  • 7. Indications and limitations of vismodegib for basal cell carcinoma--reply.
    Gill HS; Moscato EE; Silkiss RZ
    JAMA Ophthalmol; 2014 Jul; 132(7):906. PubMed ID: 25010181
    [No Abstract]   [Full Text] [Related]  

  • 8. Defining locally advanced Basal cell carcinoma.
    Maly TJ; Sligh JE
    J Drugs Dermatol; 2014 May; 13(5):528-9. PubMed ID: 24809873
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
    Lear JT
    N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909
    [No Abstract]   [Full Text] [Related]  

  • 10. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp.
    Tauber G; Pavlovsky L; Fenig E; Hodak E
    J Am Acad Dermatol; 2015 Nov; 73(5):799-801. PubMed ID: 26320385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic Findings of Tumor Lysis in Advanced Basal Cell Carcinoma Treated With Vismodegib.
    Powell EM; Stratton JS; Shendrik I; Blalock TW
    Dermatol Surg; 2016 Jul; 42(7):904-7. PubMed ID: 27191782
    [No Abstract]   [Full Text] [Related]  

  • 12. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
    Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
    [No Abstract]   [Full Text] [Related]  

  • 13. Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma.
    Khalid B; Mukherjee S; Ibrahimi S; Cannon T; Gilles E; Moreau A; Razaq M
    Am J Ther; 2018; 25(3):e394-e396. PubMed ID: 29557803
    [No Abstract]   [Full Text] [Related]  

  • 14. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 15. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment.
    Nayyar PM; Chang ALS; Sarin K; Ratner D
    Dermatol Surg; 2019 Apr; 45(4):608-610. PubMed ID: 30045109
    [No Abstract]   [Full Text] [Related]  

  • 16. Vismodegib, a hedgehog pathway inhibitor for adults with locally advanced or metastatic basal cell carcinoma.
    Wilkes GM
    Oncology (Williston Park); 2012 Aug; 26(8 Suppl Nurse Ed):31-3. PubMed ID: 25375009
    [No Abstract]   [Full Text] [Related]  

  • 17. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient.
    Koelblinger P; Dummer R; Laimer M; Hecht S; Bauer JW; Gaggl A; Kugler A
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e7-e8. PubMed ID: 28646606
    [No Abstract]   [Full Text] [Related]  

  • 18. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
    Kaehler KC; Gutzmer R; Egberts F; Hauschild A
    J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
    [No Abstract]   [Full Text] [Related]  

  • 19. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
    Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
    [No Abstract]   [Full Text] [Related]  

  • 20. Four-year experience with vismodegib hedgehog inhibitor therapy.
    Simone PD; Schwarz JM; Strasswimmer JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.